Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex skin and soft tissue infections (cSSTI) in China

Next Previous
X
Search
Trial Profile

A Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex skin and soft tissue infections (cSSTI) in China

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contezolid (Primary) ; Contezolid-acefosamil (Primary) ; Linezolid
  • Indications Skin and soft tissue infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Dec 2024 New trial record
    • 29 Nov 2024 Results presented in the MicuRx Pharmaceuticals Media Release.
    • 29 Nov 2024 According to MicuRx Pharmaceuticals media release, company will actively move forward with the New Drug Application (NDA) process of MRX-4 for injection in China and undergo technical reviews and site inspections.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top